The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

The French firm is searching for a US partner with strong foundations in the hospital sector after securing EU and China deals for its complicated urinary tract infection candidate that combines cefepime and enmetazobactam, which is nearing regulatory submission in key markets.

Operating on slim margins towards the launch of its Enos single port surgical robot, Titan Medical needs to refocus its efforts to succeed, according to its new CEO Cary Vance.